Clinical Features of COVID-19 in Pediatric Rheumatic Diseases: 2020–2022 Survey of the Pediatric Rheumatology Association of Japan
Coronavirus disease 2019 (COVID-19) in children can be compounded by concurrent diseases and immunosuppressants. For the first time, we aimed to report the clinical features of concurrent COVID-19 and pediatric rheumatic disease (PRD) in Japan. Pediatric Rheumatology Association of Japan members wer...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/15/5/1205 |
| _version_ | 1827739939782000640 |
|---|---|
| author | Hiroyuki Wakiguchi Utako Kaneko Satoshi Sato Tomoyuki Imagawa Hidehiko Narazaki Takako Miyamae |
| author_facet | Hiroyuki Wakiguchi Utako Kaneko Satoshi Sato Tomoyuki Imagawa Hidehiko Narazaki Takako Miyamae |
| author_sort | Hiroyuki Wakiguchi |
| collection | DOAJ |
| description | Coronavirus disease 2019 (COVID-19) in children can be compounded by concurrent diseases and immunosuppressants. For the first time, we aimed to report the clinical features of concurrent COVID-19 and pediatric rheumatic disease (PRD) in Japan. Pediatric Rheumatology Association of Japan members were surveyed between 1 April 2020 and 31 August 2022. Outcome measurements included the clinical features of concurrent PRD and COVID-19. Questionnaire responses were obtained from 38 hospitals. Thirty-one hospitals (82%) had children with PRD and COVID-19. The female-to-male ratio in these children (<i>n</i> = 156) was 7:3, with half aged 11–15 years. The highest proportion of children with PRD and COVID-19 was accounted for by juvenile idiopathic arthritis (52%), followed by systemic lupus erythematosus (24%), juvenile dermatomyositis (5%), scleroderma (4%), and Takayasu arteritis (3%). Of children with PRD, a significant majority (97%) were found to be asymptomatic (10%) or presented with mild symptoms (87%) of the COVID-19 infection. No severe cases or deaths were observed. Regarding the use of glucocorticoids, immunosuppressants, or biologics for PRD treatment before COVID-19, no significant difference was found between asymptomatic/mild and moderate COVID-19 in children with PRD. Therefore, COVID-19 is not a threat to children with PRD in Japan. |
| first_indexed | 2024-03-11T03:15:00Z |
| format | Article |
| id | doaj.art-ff61def6a3514567899212d66bdf0394 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-11T03:15:00Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-ff61def6a3514567899212d66bdf03942023-11-18T03:40:30ZengMDPI AGViruses1999-49152023-05-01155120510.3390/v15051205Clinical Features of COVID-19 in Pediatric Rheumatic Diseases: 2020–2022 Survey of the Pediatric Rheumatology Association of JapanHiroyuki Wakiguchi0Utako Kaneko1Satoshi Sato2Tomoyuki Imagawa3Hidehiko Narazaki4Takako Miyamae5Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube 755-8505, JapanDepartment of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, JapanDepartment of Infectious Diseases and Immunology, Saitama Children’s Medical Center, Saitama 330-8777, JapanDepartment of Infection and Immunology, Kanagawa Children’s Medical Center, Yokohama 232-0066, JapanDepartment of Pediatrics, Nippon Medical School, Tokyo 113-8602, JapanDepartment of Pediatric Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University Hospital, Tokyo 162-8666, JapanCoronavirus disease 2019 (COVID-19) in children can be compounded by concurrent diseases and immunosuppressants. For the first time, we aimed to report the clinical features of concurrent COVID-19 and pediatric rheumatic disease (PRD) in Japan. Pediatric Rheumatology Association of Japan members were surveyed between 1 April 2020 and 31 August 2022. Outcome measurements included the clinical features of concurrent PRD and COVID-19. Questionnaire responses were obtained from 38 hospitals. Thirty-one hospitals (82%) had children with PRD and COVID-19. The female-to-male ratio in these children (<i>n</i> = 156) was 7:3, with half aged 11–15 years. The highest proportion of children with PRD and COVID-19 was accounted for by juvenile idiopathic arthritis (52%), followed by systemic lupus erythematosus (24%), juvenile dermatomyositis (5%), scleroderma (4%), and Takayasu arteritis (3%). Of children with PRD, a significant majority (97%) were found to be asymptomatic (10%) or presented with mild symptoms (87%) of the COVID-19 infection. No severe cases or deaths were observed. Regarding the use of glucocorticoids, immunosuppressants, or biologics for PRD treatment before COVID-19, no significant difference was found between asymptomatic/mild and moderate COVID-19 in children with PRD. Therefore, COVID-19 is not a threat to children with PRD in Japan.https://www.mdpi.com/1999-4915/15/5/1205childrenjuvenile idiopathic arthritisomicronquestionnaireSARS-CoV-2severity |
| spellingShingle | Hiroyuki Wakiguchi Utako Kaneko Satoshi Sato Tomoyuki Imagawa Hidehiko Narazaki Takako Miyamae Clinical Features of COVID-19 in Pediatric Rheumatic Diseases: 2020–2022 Survey of the Pediatric Rheumatology Association of Japan Viruses children juvenile idiopathic arthritis omicron questionnaire SARS-CoV-2 severity |
| title | Clinical Features of COVID-19 in Pediatric Rheumatic Diseases: 2020–2022 Survey of the Pediatric Rheumatology Association of Japan |
| title_full | Clinical Features of COVID-19 in Pediatric Rheumatic Diseases: 2020–2022 Survey of the Pediatric Rheumatology Association of Japan |
| title_fullStr | Clinical Features of COVID-19 in Pediatric Rheumatic Diseases: 2020–2022 Survey of the Pediatric Rheumatology Association of Japan |
| title_full_unstemmed | Clinical Features of COVID-19 in Pediatric Rheumatic Diseases: 2020–2022 Survey of the Pediatric Rheumatology Association of Japan |
| title_short | Clinical Features of COVID-19 in Pediatric Rheumatic Diseases: 2020–2022 Survey of the Pediatric Rheumatology Association of Japan |
| title_sort | clinical features of covid 19 in pediatric rheumatic diseases 2020 2022 survey of the pediatric rheumatology association of japan |
| topic | children juvenile idiopathic arthritis omicron questionnaire SARS-CoV-2 severity |
| url | https://www.mdpi.com/1999-4915/15/5/1205 |
| work_keys_str_mv | AT hiroyukiwakiguchi clinicalfeaturesofcovid19inpediatricrheumaticdiseases20202022surveyofthepediatricrheumatologyassociationofjapan AT utakokaneko clinicalfeaturesofcovid19inpediatricrheumaticdiseases20202022surveyofthepediatricrheumatologyassociationofjapan AT satoshisato clinicalfeaturesofcovid19inpediatricrheumaticdiseases20202022surveyofthepediatricrheumatologyassociationofjapan AT tomoyukiimagawa clinicalfeaturesofcovid19inpediatricrheumaticdiseases20202022surveyofthepediatricrheumatologyassociationofjapan AT hidehikonarazaki clinicalfeaturesofcovid19inpediatricrheumaticdiseases20202022surveyofthepediatricrheumatologyassociationofjapan AT takakomiyamae clinicalfeaturesofcovid19inpediatricrheumaticdiseases20202022surveyofthepediatricrheumatologyassociationofjapan |